Add to ORKGRituximab, a type I anti-CD20 monoclonal antibody (mAb), induces incomplete B cell depletion in some patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), thus contributing to a poor clinical response. The mechanisms of this resistance remain elusive. The purpose of this study was to determine whether type II mAb are more efficient than type I mAb at depleting B cells from RA and SLE patients, whether internalization influences the efficiency of depletion, and whether Fcγ receptor type IIb (FcγRIIb) and the B cell receptor regulate this internalization process
B cell-depletion therapy, particularly using anti-CD20 treatment, has provided proof of concept that...
Background Although biological therapies have transformed the outlook for those with rheumatoid arth...
Rituximab is a monoclonal antibody against CD20 that was developed for the treatment of relapsed or ...
Objective: Rituximab, a type I anti-CD20 monoclonal antibody (mAb), induces incomplete B cell deplet...
Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of d...
Background: Determinants of response and relapse to B cell depletion in rheumatic diseases is poorly...
B-cells play an important role not only in cellular but also in humoral immunity through differentia...
B cells are believed to be central to the disease process in systemic lupus erythematosus (SLE), mak...
In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using ...
Objective A proportion of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) patients ...
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by mul...
Introduction Reconstitution of peripheral blood (PB) B cells after therapeutic depletion with the...
6Objective. The pathogenetic role of B cells in rheumatoid arthritis (RA) is under debate, but it is...
Contains fulltext : 205472.pdf (publisher's version ) (Open Access)OBJECTIVES: The...
OBJECTIVE: Safer and more effective therapies are needed for the treatment of systemic lupus erythem...
B cell-depletion therapy, particularly using anti-CD20 treatment, has provided proof of concept that...
Background Although biological therapies have transformed the outlook for those with rheumatoid arth...
Rituximab is a monoclonal antibody against CD20 that was developed for the treatment of relapsed or ...
Objective: Rituximab, a type I anti-CD20 monoclonal antibody (mAb), induces incomplete B cell deplet...
Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of d...
Background: Determinants of response and relapse to B cell depletion in rheumatic diseases is poorly...
B-cells play an important role not only in cellular but also in humoral immunity through differentia...
B cells are believed to be central to the disease process in systemic lupus erythematosus (SLE), mak...
In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using ...
Objective A proportion of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) patients ...
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by mul...
Introduction Reconstitution of peripheral blood (PB) B cells after therapeutic depletion with the...
6Objective. The pathogenetic role of B cells in rheumatoid arthritis (RA) is under debate, but it is...
Contains fulltext : 205472.pdf (publisher's version ) (Open Access)OBJECTIVES: The...
OBJECTIVE: Safer and more effective therapies are needed for the treatment of systemic lupus erythem...
B cell-depletion therapy, particularly using anti-CD20 treatment, has provided proof of concept that...
Background Although biological therapies have transformed the outlook for those with rheumatoid arth...
Rituximab is a monoclonal antibody against CD20 that was developed for the treatment of relapsed or ...